QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NASDAQ:KTTA

Pasithea Therapeutics - KTTA Stock Forecast, Price & News

$0.70
+0.04 (+6.03%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.65
▼
$0.73
50-Day Range
$0.55
▼
$1.03
52-Week Range
$0.54
▼
$1.54
Volume
552,642 shs
Average Volume
123,073 shs
Market Capitalization
$20.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

KTTA stock logo

About Pasithea Therapeutics (NASDAQ:KTTA) Stock

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Stock News Headlines

January 25, 2023 | seekingalpha.com
KTTA Pasithea Therapeutics Corp.
January 23, 2023 | americanbankingnews.com
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Significant Drop in Short Interest
January 31, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
January 18, 2023 | finance.yahoo.com
Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004
January 16, 2023 | finance.yahoo.com
Pasithea Therapeutics Corp. (KTTA)
December 14, 2022 | finance.yahoo.com
Majority of Stockholders Support Pasithea Directors at Special Meeting
December 6, 2022 | finance.yahoo.com
Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference
November 28, 2022 | finance.yahoo.com
Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time
January 31, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 22, 2022 | finance.yahoo.com
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
October 17, 2022 | finance.yahoo.com
Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium
October 14, 2022 | finance.yahoo.com
Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive
October 13, 2022 | finance.yahoo.com
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
October 12, 2022 | finance.yahoo.com
Pasithea Therapeutics Acquires AlloMek Therapeutics
October 10, 2022 | markets.businessinsider.com
EQS-News: New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
October 10, 2022 | finance.yahoo.com
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
October 5, 2022 | nasdaq.com
We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Rate
October 3, 2022 | finance.yahoo.com
Pasithea Therapeutics to Call Special Meeting of Stockholders
October 3, 2022 | markets.businessinsider.com
EQS-News: Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
September 28, 2022 | finance.yahoo.com
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
September 15, 2022 | finance.yahoo.com
Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz
September 12, 2022 | finance.yahoo.com
Here's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation
September 6, 2022 | finance.yahoo.com
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
August 24, 2022 | finance.yahoo.com
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
August 18, 2022 | finance.yahoo.com
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
August 11, 2022 | finanznachrichten.de
Financialnewsmedia.com: Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022 | seekingalpha.com
Pasithea jumps 21% on animal data for multiple sclerosis candidate
See More Headlines
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Company Calendar

Today
1/31/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KTTA
CUSIP
N/A
CIK
1841330
Web
www.pasithea.com
Phone
702-514-4174
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,170,000.00
Net Margins
-3,133.55%
Pretax Margin
-3,133.55%
Return on Equity
-16.40%
Return on Assets
-15.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
29.37
Quick Ratio
29.37

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
1,027.92
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.23 per share
Price / Book
0.32

Miscellaneous

Outstanding Shares
29,250,000
Free Float
27,348,000
Market Cap
$20.56 million
Optionable
Not Optionable
Beta
-0.04

Key Executives

  • Dr. Lawrence Steinman BA (Age 74)
    M.D., Exec. Chairman & Co-Founder
    Comp: $72.92k
  • Dr. Tiago Reis Marques (Age 45)
    CEO & Director
    Comp: $243.75k
  • Mr. Daniel H. Schneiderman (Age 44)
    Chief Financial Officer
  • Dr. Yassine Bendiabdallah Ph.D. (Age 37)
    COO & Head of UK Clinics

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KTTA Stock - Frequently Asked Questions

How have KTTA shares performed in 2023?

Pasithea Therapeutics' stock was trading at $0.6417 at the beginning of the year. Since then, KTTA stock has increased by 9.5% and is now trading at $0.7029.
View the best growth stocks for 2023 here.

When did Pasithea Therapeutics IPO?

(KTTA) raised $17 million in an initial public offering on Wednesday, September 15th 2021. The company issued 2,898,551 shares at $5.00-$7.00 per share.

What is Pasithea Therapeutics' stock symbol?

Pasithea Therapeutics trades on the NASDAQ under the ticker symbol "KTTA."

How do I buy shares of Pasithea Therapeutics?

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pasithea Therapeutics' stock price today?

One share of KTTA stock can currently be purchased for approximately $0.70.

How much money does Pasithea Therapeutics make?

Pasithea Therapeutics (NASDAQ:KTTA) has a market capitalization of $20.56 million and generates $20,000.00 in revenue each year.

How can I contact Pasithea Therapeutics?

Pasithea Therapeutics' mailing address is 1111 Lincoln Road Suite 500, Miami Beach FL, 33139. The official website for the company is www.pasithea.com. The company can be reached via phone at 702-514-4174 or via email at lwilson@insitecony.com.

This page (NASDAQ:KTTA) was last updated on 1/31/2023 by MarketBeat.com Staff